keyword
MENU ▼
Read by QxMD icon Read
search

Migrain treatment

keyword
https://www.readbyqxmd.com/read/28749241/considerations-for-adhd-in-the-child-with-epilepsy-and-the-child-with-migraine
#1
David W Dunn, Jennifer Downs, Julianne Giust
Attention Deficit Hyperactivity Disorder (ADHD) is a common comorbid condition in children with epilepsy and migraine. Treatment of ADHD in children with epilepsy or migraine is essential but clinicians may overlook symptoms of ADHD and avoid appropriate use of medications that may reduce symptoms of ADHD without compromising treatment of epilepsy or migraine. Areas covered: PubMed was searched for articles on ADHD and epilepsy or migraine. Key papers were reviewed for additional articles. Areas of interest were: epidemiology, etiological factors, and treatment with emphasis on therapy...
July 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28748680/factors-associated-with-favorable-outcome-of-topiramate-migraine-prophylaxis-in-pediatric-patients
#2
Il Han Yoo, WooJoong Kim, Hunmin Kim, Byung Chan Lim, Hee Hwang, Jong Hee Chae, Jieun Choi, Ki Joong Kim
BACKGROUND AND PURPOSE: There are few studies that have investigated predictive factors related to migraine prophylaxis of which produced inconsistent results. The aim of this study was to identify factors that can predict the treatment response to topiramate prophylaxis in pediatric patients with migraine. METHODS: One hundred and thirteen patients who were older than 7 years and received topiramate for at least 3 months were recruited from the Seoul National University Bundang Hospital outpatient clinic from 2005 to 2014...
July 2017: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/28748672/is-there-an-association-between-migraine-and-gastrointestinal-disorders
#3
REVIEW
Michael Doulberis, Christian Saleh, Stefan Beyenburg
Migraine is a primary episodic headache disorder that represents a substantial burden and disability worldwide. Its pathogenesis is multifactorial and remains hitherto poorly elucidated. An interesting but less-well-known association is that between migraine and gastrointestinal disorders. We have reviewed the literature for relevant papers reporting on the clinical association between migraine and gastrointestinal symptoms. Several studies have shown different gastrointestinal diseases to be associated with migraine, but the underlining pathophysiology remains elusive...
July 2017: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/28748412/pharmacokinetics-of-dfn-15-a-novel-oral-solution-of-celecoxib-versus-celecoxib-400-mg-capsules-a-randomized-crossover-study-in-fasting-healthy-volunteers
#4
Arindam Pal, Srinivas Shenoy, Anirudh Gautam, Sagar Munjal, Jing Niu, Mathangi Gopalakrishnan, Joga Gobburru
BACKGROUND: COX-2 inhibitors can be effective for acute migraine, but none is supplied in a rapidly absorbed, ready-to-use oral liquid formulation. DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura. Clinical studies with this formulation are ongoing. OBJECTIVES: The objectives of the present study were to compare the bioavailability of DFN-15 with that of the commercial formulation of celecoxib 400-mg oral capsules (Celebrex(®)) and to determine the dose proportionality of DFN-15 in healthy fasted volunteers...
July 26, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28748384/the-more-vivid-the-imagination-the-better-the-role-of-the-vividness-of-imagination-in-vasoconstriction-training-and-vasodilatation-training
#5
Julia E Graef, Winfried Rief, Yvonne Nestoriuc, Cornelia Weise
Blood volume pulse biofeedback represents an effective non-pharmacological treatment for migraine. However, the underlying mechanisms of blood volume pulse biofeedback are still unclear. This study investigated the influence of vividness of imagination, private body consciousness, perfectionism, and general self-efficacy on physiological (blood volume pulse amplitude) and psychological (session performance rated by participants and by trainers) success. Changes in skin conductance and skin temperature indicating habituation to training context were examined...
July 26, 2017: Applied Psychophysiology and Biofeedback
https://www.readbyqxmd.com/read/28747114/prevalence-characteristics-and-management-of-headache-experienced-by-people-with-schizophrenia-and-schizoaffective-disorder-a-cross-sectional-cohort-study
#6
Joanne Connaughton, Benedict Wand
OBJECTIVES: Headache is the most common type of pain reported by people with schizophrenia. This study aimed to establish prevalence, characteristics and management of these headaches. METHODS: One hundred participants with schizophrenia/schizoaffective disorder completed a reliable and valid headache questionnaire. Two clinicians independently classified each headache as migraine, tension-type, cervicogenic or other. RESULTS: The 12-month prevalence of headache (57%) was higher than the general population (46%) with no evidence of a relationship between psychiatric clinical characteristics and presence of headache...
August 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28743296/case-report-of-hypnic-headache-a-rare-headache-disorder-with-nocturnal-symptoms
#7
Kanishka P Dissanayake, Damindi P Wanniarachchi, Udaya K Ranawaka
BACKGROUND: Headache is one of the commonest complaints reported to physicians worldwide. Yet, arriving at the proper diagnosis can be a challenge in many patients. Although most headaches belong to common categories of migraine and tension-type headache, which are diagnosed and managed relatively easily, several uncommon headache disorders can lead to delays in diagnosis. Certain medications are more efficacious than others in managing these headache disorders, hence establishing the correct diagnosis is of paramount importance...
July 25, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28742242/multidisciplinary-team-treatment-approaches-to-chronic-daily-headaches
#8
Soma Sahai-Srivastava, Erica Sigman, Ashley Uyeshiro Simon, Lyssa Cleary, Lori Ginoza
OBJECTIVE: In this review, we focus on nonmedication treatment approaches to chronic daily headaches and chronic migraine. We review the current scientific data on studies using multimodal treatments, especially physical therapy and occupational therapy, and provide recommendations on the formation of interdisciplinary headache teams. BACKGROUND: Chronic daily headache, which includes chronic migraine, is a particularly challenging clinical entity which often involves multiple headache types and comorbidities...
July 25, 2017: Headache
https://www.readbyqxmd.com/read/28742215/complementary-and-alternative-medicine-use-among-us-adults-with-headache-or-migraine-results-from-the-2012-national-health-interview-survey
#9
Yan Zhang, Jeff A Dennis, Matthew J Leach, Felicity L Bishop, Holger Cramer, Vincent C H Chung, Craig Moore, Romy Lauche, Ron Cook, David Sibbritt, Jon Adams
BACKGROUND: Given the safety concerns regarding pharmacological agents, and the considerable impact of headache and migraine on the sufferer's quality of life, many people seek other treatment options beyond conventional medication and care to address their symptoms; this includes complementary and alternative medicine (CAM). Some CAM interventions have shown promising results in clinical trials of headache and migraine management. Nonetheless, there has been little research exploring the reasons for using CAM, and the types of CAM used, among this population...
July 25, 2017: Headache
https://www.readbyqxmd.com/read/28741429/rapid-systemic-delivery-of-zolmitriptan-using-an-adhesive-dermally-applied-microarray
#10
Donald J Kellerman, Mahmoud Ameri, Stewart J Tepper
Adhesive Dermally-Applied Microarray (ADAM) is a device for intracutaneous drug administration consisting of a 3 cm(2) disposable array of drug-coated titanium microprojections on an adhesive backing. It is applied using a low cost, reusable, handheld applicator. Microprojections penetrate the stratum corneum, delivering drug proximal to capillaries with limited likelihood of pain. The pharmacokinetics of zolmitriptan delivery using ADAM was evaluated in 20 healthy volunteers. Median tmax was <20 min, comparable to subcutaneous sumatriptan...
July 25, 2017: Pain Management
https://www.readbyqxmd.com/read/28741118/strategies-to-decrease-injection-site-pain-in-botulinum-toxin-therapy
#11
Lejla Paracka, Katja Kollewe, Florian Wegner, Dirk Dressler
Botulinum toxin is now used for numerous indications including dystonias, spasticity, cerebral palsy, hyperhidrosis, cosmetics and chronic migraine. It has to be injected into its target tissues thus causing injection site pain. We wanted to compare the efficacy of various analgesic interventions suggested for reduction of injection site pain. In 13 healthy controls, pain thresholds in the fingertips II and III bilaterally were determined by the Mechanical Pain Threshold Test and the Repetitive Pain Stimulation Test at baseline and under nitrous oxide/oxygen, ice spray, local anaesthetic cream and forearm ischaemia...
July 24, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/28741060/efficacy-of-modified-wuzhuyu-decoction-granule-for-migraine-patients-with-cold-and-stasis-obstructing-meridian-syndrome-a-randomized-double-blind-placebo-controlled-trial
#12
Hong-Wei Liu, Yi-Huai Zou, Ke-Gang Cao, Li-Hua Yu, Yong Zhang, Cai-Hong Fu, Da-Yong Ma
OBJECTIVE: To study the efficacy of modified Wuzhuyu Decoction Granule (, MWDG) in the treatment of migraine patients with cold and stasis obstructing meridian syndrome. METHODS: This study was a randomized, double-blind, placebo-controlled trial. A total of 78 migraine patients with cold and stasis obstructing meridian syndrome were recruited and randomly assigned by a ratio of 2:1 into a treatment group (51 cases) and a placebo group (27 cases). Patients in the treatment group were treated with MWDG while placebo granules were applied in the control group...
July 25, 2017: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/28738036/cannabis-guidelines%C3%A2
#13
Lisa Kennedy Sheldon
Cannabis has been used for centuries in the treatment of medical conditions. Cannabis has been recommended for appetite, anxiety, depression, sleep, and migraines. However, the stigma associated with cannabis as a recreational drug has created challenges to the legitimacy and social acceptance of cannabis for medical purposes in the United States.
August 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28736918/phase-1-randomized-double-blind-placebo-controlled-single-dose-and-multiple-dose-studies-of-erenumab-in-healthy-subjects-and-patients-with-migraine
#14
Jan de Hoon, Anne Van Hecken, Corinne Vandermeulen, Lucy Yan, Brian Smith, Jiyun Sunny Chen, Edgar Bautista, Lisa Hamilton, Javier Waksman, Thuy Vu, Gabriel Vargas
Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. We report the data from two phase 1 studies assessing the safety, pharmacokinetics (PK), and pharmacodynamics of single and multiple administrations of erenumab in healthy subjects and patients with migraine. The results indicate that the PK profile of erenumab is nonlinear from 1 mg to 70 mg and the linear portion of the clearance from 70 mg to 210 mg is consistent with other human immunoglobulin (Ig)G2 antibodies...
July 24, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28734941/sleep-chronic-pain-and-opioid-risk-for-apnea
#15
REVIEW
Serguei Marshansky, Pierre Mayer, Dorrie Rizzo, Marc Baltzan, Ronald Denis, Gilles J Lavigne
Pain is an unwelcome sleep partner. Pain tends to erode sleep quality and alter the sleep restorative process in vulnerable patients. It can contribute to next-day sleepiness and fatigue, affecting cognitive function. Chronic pain and the use of opioid medications can also complicate the management of sleep disorders such as insomnia (difficulty falling and/or staying asleep) and sleep-disordered breathing (sleep apnea). Sleep problems can be related to various types of pain, including sleep headache (hypnic headache, cluster headache, migraine) and morning headache (transient tension type secondary to sleep apnea or to sleep bruxism or tooth grinding) as well as periodic limb movements (leg and arm dysesthesia with pain)...
July 19, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28734169/development-and-psychometric-validation-of-the-headache-screening-questionnaire-dutch-version
#16
Hedwig A van der Meer, Corine M Visscher, Raoul H H Engelbert, Wim M Mulleners, Maria W G Nijhuis-van der Sanden, Caroline M Speksnijder
BACKGROUND: Headache is a common disorder which may lead to substantial socio-economic loss. Treatment options include self-management strategies, medication and physiotherapy. Physiotherapists need to be able to screen for the presence of migraine and tension-type headache (TTH), so they can adjust their treatment strategies to the type of headache. A quick screening questionnaire to recognize migraine and TTH in the physiotherapy practice is needed. OBJECTIVE: The aim of this study was to create a headache screening questionnaire based on the ICHD-3 beta criteria for migraine and TTH, and to establish its content and criterion validity...
July 4, 2017: Musculoskeletal Science & Practice
https://www.readbyqxmd.com/read/28733943/onabotulinumtoxina-injections-in-chronic-migraine-targeted-to-sites-of-pericranial-myofascial-pain-an-observational-open-label-real-life-cohort-study
#17
Danièle Ranoux, Gaelle Martiné, Gaëlle Espagne-Dubreuilh, Marlène Amilhaud-Bordier, François Caire, Laurent Magy
BACKGROUND: OnabotulinumtoxinA has proven its efficacy in reducing the number of headache days in chronic migraine (CM) patients. The usual paradigm includes 31 pericranial injection sites with low dose (5 U) per site. The aim of this study is to present the results obtained using a simpler injection protocol of onabotulinumtoxinA, with injection sites targeted to pericranial myofascial sites of pain. METHODS: Observational, open label, real-life, cohort study...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28733711/a-brief-history-of-neurological-botulinum-toxin-therapy-in-germany
#18
REVIEW
Dirk Dressler, Peter Roggenkaemper
Botulinum toxin (BT) has long been infamous in food safety and biological warfare. In the early 1970s, Alan B Scott of San Francisco invented its therapeutic use originally in extraocular eye muscles to treat strabismus using a therapeutic BT type A preparation provided by Edward J Schantz and Eric A Johnson. Subsequently a large number of medical indications based on motor and glandular hyperactivity and-most recently-chronic migraine are now treated by BT therapy. BT's highly specific and elaborate mechanism of action represents a completely novel therapeutic principle which will have consequences far beyond existing indications...
July 21, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/28731567/integration-of-white-matter-network-is-associated-with-interindividual-differences-in-psychologically-mediated-placebo-response-in-migraine-patients
#19
Jixin Liu, Shaohui Ma, Junya Mu, Tao Chen, Qing Xu, Wanghuan Dun, Jie Tian, Ming Zhang
Individual differences of brain changes of neural communication and integration in the modular architecture of the human brain network exist for the repeated migraine attack and physical or psychological stressors. However, whether the interindividual variability in the migraine brain connectome predicts placebo response to placebo treatment is still unclear. Using DTI and graph theory approaches, we systematically investigated the topological organization of white matter networks in 71 patients with migraine without aura (MO) and 50 matched healthy controls at three levels: global network measure, nodal efficiency, and nodal intramodule/intermodule efficiency...
July 21, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/28730894/low-5-ht1b-receptor-binding-in-the-migraine-brain-a-pet-study
#20
Marie Deen, Hanne D Hansen, Anders Hougaard, Sofi da Cunha-Bang, Martin Nørgaard, Claus Svarer, Sune H Keller, Carsten Thomsen, Messoud Ashina, Gitte M Knudsen
Background The pathophysiology of migraine may involve dysfunction of serotonergic signaling. In particular, the 5-HT1B receptor is considered a key player due to the efficacy of 5-HT1B receptor agonists for treatment of migraine attacks. Aim To examine the cerebral 5-HT1B receptor binding in interictal migraine patients without aura compared to controls. Methods Eighteen migraine patients, who had been migraine free for >48 hours, and 16 controls were scanned after injection of the 5-HT1B receptor specific radioligand [(11)C]AZ10419369 for quantification of cerebral 5-HT1B receptor binding...
January 1, 2017: Cephalalgia: An International Journal of Headache
keyword
keyword
67117
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"